Oura, the Finnish biometric ring maker valued at $2.2 billion, has postponed its initial public offering indefinitely, citing market uncertainty as the primary reason for the delay.
The decision represents a significant setback for the company and its existing investors, who had been preparing for a public market debut. Oura had been targeting a listing that would have valued the company at the $2.2 billion figure, though specific details about the IPO timing or lead underwriters were not disclosed ahead of the postponement announcement.
The company manufactures smart rings that track sleep, heart rate, body temperature, and other health metrics. Oura competes in the health-tracking wearables space alongside companies like Apple, Fitbit (owned by Google), Samsung, and Whoop. The ring format differentiates Oura from traditional smartwatch competitors, offering a less obtrusive way to collect continuous biometric data.
Market conditions have proven hostile for IPOs throughout 2023 and into 2024. Public market volatility, rising interest rates, and investor skepticism toward unprofitable growth companies have dried up IPO pipelines across sectors. Healthcare and consumer tech have been particularly affected, with numerous companies either delaying or canceling public debuts entirely.
The postponement directly impacts Oura's expansion plans. The company had identified specific uses for IPO proceeds, including product development, international expansion, and potential acquisitions. Those initiatives now face delays as the company reassesses its capital needs and timeline. Existing shareholders, including venture capital firms and early investors, also see their liquidity events pushed back indefinitely.
Oura has raised venture funding from notable investors in previous rounds. The company remains unprofitable but has grown its user base significantly, selling millions of rings globally. The device costs around $299 retail, with subscription services providing recurring revenue through health insights and coaching features.
The broader wearables market continues expanding despite the pullback in IPO activity. Consumer interest in health monitoring remains strong, particularly post-pandemic. However, investors have grown more skeptical about valuation multiples for hardware companies with subscription components.
Other health-tech companies have faced similar pressures. Peloton, which went public in 2019, saw its stock collapse after overexpanding during the pandemic. That cautionary tale has made VCs and public market investors more conservative about funding and taking hardware-plus-subscription companies public.
Oura's delay reflects a broader maturation in the venture market. Companies no longer feel pressure to rush to IPO windows, instead opting to remain private longer if conditions don't support premium valuations. The company may pursue alternative paths to liquidity, including secondary stock sales to private investors or simply remaining private while self-funding operations.
The company has not announced specific plans for the postponed proceeds or when it might revisit a public offering. Market conditions would need to stabilize materially before Oura revisits its IPO ambitions.